John Hussman's JAZZ Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 4,200 shares of Jazz Pharmaceuticals plc (JAZZ) worth $794,010, representing 0.17% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in JAZZ, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 21,000 shares. Largest reduction occurred in Q1 2018, reducing 25,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Jazz Pharmaceuticals plc (JAZZ) Holding Value Over Time
Track share changes against reported price movement
Quarterly Jazz Pharmaceuticals plc (JAZZ) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +4,200 | New Buy | 4,200 | $189.05 |
| Q3 2025 | -21,000 | Sold Out | 0 | $0.00 |
| Q2 2025 | +21,000 | New Buy | 21,000 | $106.12 |
| Q2 2023 | -12,400 | Sold Out | 0 | $0.00 |
| Q3 2022 | +2,000 | Add 19.23% | 12,400 | $133.31 |
| Q2 2022 | +5,200 | Add 100.00% | 10,400 | $156.06 |
| Q1 2022 | -10,400 | Reduce 66.67% | 5,200 | $155.58 |
| Q4 2021 | -9,200 | Reduce 37.10% | 15,600 | $127.37 |
| Q3 2021 | +3,200 | Add 14.81% | 24,800 | $130.20 |
| Q1 2021 | +1,100 | Add 5.37% | 21,600 | $164.35 |
| Q4 2020 | +250 | Add 1.23% | 20,500 | $165.07 |
| Q2 2020 | +5,000 | Add 32.79% | 20,250 | $110.32 |
| Q1 2020 | +10,250 | Add 205.00% | 15,250 | $99.74 |
| Q4 2019 | +5,000 | New Buy | 5,000 | $149.20 |
| Q2 2019 | -400 | Sold Out | 0 | $0.00 |
| Q1 2019 | -20,000 | Reduce 98.04% | 400 | $142.50 |
| Q4 2018 | +20,400 | New Buy | 20,400 | $123.97 |
| Q1 2018 | -25,000 | Sold Out | 0 | $0.00 |
| Q4 2017 | +25,000 | New Buy | 25,000 | $134.64 |
John Hussman's Jazz Pharmaceuticals plc Investment FAQs
John Hussman first purchased Jazz Pharmaceuticals plc (JAZZ) in Q4 2017, acquiring 25,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Jazz Pharmaceuticals plc (JAZZ) for 23 quarters since Q4 2017.
John Hussman's largest addition to Jazz Pharmaceuticals plc (JAZZ) was in Q4 2017, adding 25,000 shares worth $3.37 M.
According to the latest 13F filing for Q1 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 4,200 shares of Jazz Pharmaceuticals plc (JAZZ), valued at approximately $794,010.
As of the Q1 2026 filing, Jazz Pharmaceuticals plc (JAZZ) represents approximately 0.17% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Jazz Pharmaceuticals plc (JAZZ) was 25,000 shares, as reported at the end of Q4 2017.